Abstract: Disclosed herein is a ganetespib-containing particle, which includes an active ingredient selected from ganetespib, a pharmaceutically acceptable salt of ganetespib, and a combination thereof, and an amphiphilic chitosan-based carrier carrying the active ingredient. Also disclosed herein are a pharmaceutical composition including the ganetespib-containing particle, and use of such pharmaceutical composition in treating cancer.

Abstract: Disclosed herein are heat-stable dry powders which include peptides or protein such as oxytocin for use as a pharmaceutical composition. The composition is highly stable at increased temperatures and relatively high humid environments, and are intended for storage at room temperature with an improved shelf-life. In particular, the dry powders are intended for inhalation, however, other routes of administration can be used when reconstituted in solution.

Abstract: Semiconductor nanocrystals prepared using a mixture of organic ligands (e.g., oxoacids), as well as compositions, kits, and methods of using such semiconductor nanocrystals are disclosed.

Abstract: Disclosed herein are oral dose formulations of aldosterone receptor antagonists, such as eplerenone and spironolactone, for the treatment of heart failure with preserved ejection fraction and uncontrolled hypertension.

Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).

Abstract: Disclosed are a pharmaceutical use of a gold cluster and a substance containing the gold cluster and the preparation method and use thereof. The gold cluster and substance containing the gold cluster can inhibit the aggregation of A? and ?-syn, has excellent effects on the levels of cell models and animal models, and can be used to prepare drugs for preventing and treating Alzheimer's disease and/or Parkinson's disease.

Abstract: The invention relates to the compounds or its pharmaceutical acceptable polymorphs, solvates, enantiomers, stereoisomers and hydrates thereof. The pharmaceutical compositions comprising an effective amount of compounds of formula I, formula II, formula III, formula IV, formula V, formula VI, formula VII, formula VIII, formula IX, formula X, formula XI, formula XII, formula XIII, formula XIV and formula XV and the methods for the treatment of chronic pain may be formulated for oral, buccal, rectal, topical, transdermal, transmucosal, lozenge, spray, intravenous, oral solution, buccal mucosal layer tablet, parenteral administration, syrup, or injection. Such compositions may be used to treatment of chronic pain.

Abstract: An aerosol-generating system is provided, including an aerosol-generating device including a heater element, and an aerosol-generating article configured to engage with the aerosol-generating device. The aerosol-generating article includes a medicament source, a volatile delivery enhancing compound source, and at least one frangible barrier sealing the medicament source and the volatile delivery enhancing compound source. The aerosol-generating system also includes at least one piercing element disposed on one of the aerosol-generating device and the aerosol-generating article, the at least one piercing element being configured to pierce the at least one frangible barrier when activated by a user.

Abstract: A composition and method for treating a mammal infected with a virus therein, and an inhalation delivery system for prevention and treatment of upper respiratory tract viruses, by administering a therapeutic dose of the composition to the mammal. The composition includes: microparticles and/or nanoparticles, wherein a pharmaceutically active agent, corticosteroid and/or hydroxychloroquine, niclosamide, and/or favipiravir, and a zinc salt are incorporated in the microparticles and/or nanoparticles. The pharmaceutically active agent is unfractionated heparin (UFH), Low Molecular Weight Heparin (LMWH), sulfated non-anticoagulant heparin (S-NACH), other glycosaminoglycans (GAGs), or combinations thereof.

Abstract: Novel, nano-structured particles are formed by introducing a selected solid of interest into a structured fluid matrix formed by a dispersion of a small molecule host vessel components, such as a native or modified polysaccharide, cavitand, simple sugar, disaccharide, simple polyol or other similarly structured molecule known to be useful as a host vessel, in an acidic medium or other solvent, whereby the particle size of the introduced solid is reduced and or limited in the structured fluid matrix, by incorporation into or attachment to, the host vessel. The simple, one-batch mixing process results in stabilized colloidal dispersions of the nanoparticles of a variety of solids of varying scope and function and useful in a wide variety of applications, including without limitation ceramic materials, such as hexagonal boron nitride.

Abstract: The present invention relates to the formulations, methods and kits for reducing cytokine interleukin-17 (IL-17 or IL-17A) levels in both broncheoalveolar lavage fluid (BALF) and blood/serum and/or for the inhibition of p38 mitogen activating protein kinase (MAPK) activity involving the use of 17?-hydroxyprogesterone caproate (17-OHPC) or derivatives thereof. The formulation may be in the form of an inhalant containing effective amounts of 17-OHPC, and the formulation may be used in a method to treat IL-17 cytokine and/or p38 MAPK mediated auto-immune and auto-inflammatory diseases. Such diseases may include glucocorticoid (GC) insensitive related diseases or conditions. In alternate embodiment, the formulation may include the combined use of budesonide (BUD) with 17-OPHC.

Abstract: The present invention provides wound healing compounds, compositions thereof, and methods of treatment using the same.

Abstract: A polar solvent solution of the present invention is a polar solvent solution in which a solute containing a polyamine acid is dissolved in a polar solvent. An inorganic salt is added to the solution, and a mole ratio of moisture to the inorganic salt in the solution is 2.5×m×n or less, where m represents the number of cations forming the inorganic salt and n represents a charge number of the cation. A production method of the present invention is a method for producing the above solution, including: changing at, least one of a moisture content and a content of the inorganic salt in the solution to adjust a viscosity of the solution. Thus, the present invention provides a polar solvent solution whose viscosity can be easily adjusted to a desired value and thus enables stable spinning and casting when used as dopes for spinning, film, etc., and methods for producing the same.

Abstract: A dispersion of formononetin solid lipid nanoparticles and process for its preparation, namely having (i) a core system comprising formononetin, a lipid base, and a fluid medium, and (ii) an emulsifier system comprising an emulsifier, and water. The dispersion of formononetin solid lipid nanoparticles of the present disclosure can be used for treating cancer, osteoporosis, diabetes, and inflammation. The dispersion of formononetin solid lipid nanoparticles of the present disclosure are biocompatible, biodegradable, has improved solubility, has enhanced controlled drug release profile and are stable.

Abstract: Provided is an organic solvent-free method for producing a plurality of microsphere having an average diameter of less than 500 ?m in diameter and having average contact angle ?c greater than 140°, consisting essentially of a biocompatible hot-melt carrier vehicle and a payload substance to be delivered, including melting and mixing a polymer carrier vehicle which is solid at room temperature and at least one payload substance, and dispensing microportions of the molten mixture through a droplet-forming space onto a cooled solid superoleophobic surface.

Abstract: There is provided a planar structural body 1 comprising a fibrous carbon nanohorn aggregate 2 in which a plurality of single-walled carbon nanohorns are aggregated in a fibrous state, and particularly the planar structural body in which a globular carbon nanohorn aggregate 3 is mixed is used. The planar structural body comprising such a fibrous carbon nanohorn aggregate can be used for electrode materials for lithium ion batteries, fuel cells, capacitors, electrochemical actuators, air cells, solar cells, and the like, and can be used also for electromagnetic shields, thermoconductive sheets, heat-dissipating sheets, protecting sheets, filters and absorbing materials.

Abstract: The present disclosure relates to an oral, extended release, abuse deterrent dosage form containing a controlled release agent, a second agent and/or polyethylene glycol, and at least one active pharmaceutical ingredient susceptible to abuse. The dosage form is stable at high temperatures and abuse deterrent to oral and parenteral administration via dose dumping, extraction, and purification. The present disclosure also relates to processes of preparing the dosage form.

Abstract: The disclosure provides the use of particular substituted heterocycle fused gamma-carboline compounds as pharmaceuticals for the treatment of residual symptoms of psychosis or schizophrenia. The disclosure also provides novel long acting injectable formulations of particular substituted heterocycle fused gamma-carboline compounds and use of such long acting injectable formulations for the treatment of residual symptoms of psychosis or schizophrenia.

Abstract: Two vial containing kits containing aspirin for intravenous administration are disclosed. The first vial contains a lyophilized mixture of aspirin in crystalline form, a bulking agent such as mannitol and a surfactant. The second vial includes an aqueous diluent such as water for injection and a basifying agent such as Tris.

Abstract: Genetically engineered Foot and Mouth Disease Virus (FMDV) and related engineered proteins and polynucleotides, nanolipoprotein particles, compositions, methods and systems are described. The genetically engineered FMDV is modified by the strategic insertion of a protein tag into select regions of the FMDV genome which encode viral proteins that are exposed on the surface of the FMDV viral capsid. The inserted protein tag is displayed as a decoration or attachment on the viral capsid surface.

Abstract: Methods of weight management for a subject are provided. Generally the methods comprising: administering an effective amount to the small intestine and/or large intestine of the subject of at least one agent that increases oxygen tension and/or redox potential and/or pH in the colon of the subject to thereby manage the weight of the subject. Also provided are compositions comprising at least one agent that increases oxygen tension and/or redox potential and/or pH, wherein the composition is formulated for delivery of an effective amount of the at least one agent to the small intestine and/or large intestine of a subject following oral ad ministration of the composition to the subject.

Abstract: Compositions comprising a corticosteroid and a beta-adrenergic are useful for treating inflammatory or obstructive airways diseases.

Abstract: An implant for the repair of bone and cartilage that includes a cell conductive zone that contains biopolymeric fibers and an osteoconductive zone that contains biopolymeric fibers and calcium-containing mineral particles. The biopolymeric fibers from one zone overlap with the fibers in the other zone forming a stable physical and mechanical integration of the two zones, thus conferring in vivo stability to the implant.

Abstract: Provided herein are methods and compositions for modulating a microorganism's response to an antimicrobial agent. In one embodiment, the method comprises contacting the microorganism with an antimicrobial agent and bicarbonate. In one embodiment, provided herein are methods for treating a microbial infection comprising administering to a subject in need an effective amount of (i) bicarbonate and (ii) an antimicrobial agent. Also provided herein are methods of screening for antimicrobial compounds.

Abstract: Example methods and apparatuses are disclosed for providing tissue ablation through electrolysis, electroporation, or a combination thereof. A way to deliver the combination through a pulse that has an element of gradual decay and can thereby reduce both muscle contraction and electric breakdown discharge at the electrodes is disclosed. The apparatus disclosed may include an electrode, a power supply, and a controller. The controller may control a charge applied to the electrode to induce a direct current through a treatment site to produce electrolysis products and a voltage to produce electroporation. The duration and magnitude of the charge applied may determine the dose of the products and the degree of the permeabilization of cells in the treatment site.

Abstract: The present invention relates to nanoparticles for encapsulating biologically active compounds, comprising a matrix of new polymer conjugates. The invention also relates to a process for producing both the conjugates and nanoparticles, to compositions containing said conjugates or nanoparticles, and applications thereof. The invention is applicable in the pharmaceutical sector and in the nanotechnology sector.

Abstract: The disclosure relates to a method of treating cancer by administering to the subject a therapeutically effective amount of a composition comprising pyrvinium pamoate, optionally in combination with at least one additional therapeutic agent or modality.

Abstract: The present invention relates to stable oral pharmaceutical compositions of sitagliptin base and processes for the preparation thereof.

Abstract: The present disclosure provides improved film based pharmaceutical products containing uniformly distributed drug or active agent particles (e.g., to achieve improved/excellent dissolution control including enhancing dissolution and bioavailability and/or product uniformity). More particularly, the present disclosure provides improved systems/methods for fabricating film based pharmaceutical products by utilizing higher surface modified micronized drug or active agent powders and film forming precursors and drying methods that accomplish improved/efficient drying and provide improved/excellent content uniformity of active pharmaceutical agents in the fabricated film based pharmaceutical products. In exemplary embodiments, the present disclosure provides for an easier means of directly incorporating dry micronized poorly water-soluble drugs or active agent particles (e.g., fenofibrate (“FNB”)) into films.

Abstract: The present invention relates to compositions of benefit agent containing delivery particles and slurries comprising benefit agent containing delivery particles, compositions comprising the particles, and processes for making and using the aforementioned particles and compositions. Such slurries and benefit agent containing delivery particles are stable and when employed in compositions, for example, cleaning or fabric care compositions, the particles in such slurries increase the efficiency of benefit agent delivery, thereby allowing reduced amounts of benefit agents to be employed. In addition to allowing the amount of benefit agent to be reduced, such particles allow a broad range of benefit agents to be employed. The compositions can comprise particles, cakes, powders, particulates, aggregates, aggregate clusters and slurries comprising the benefit agent containing delivery particles.

Abstract: The present invention relates to an ophthalmic composition for lowering an intraocular pressure, the composition comprising latanoprost, polyoxyl 40 hydrogenated castor oil, and sorbitol.

Abstract: The present invention provides microparticles comprising a sulphur-containing compound, such as cysteamine, or a pharmaceutically acceptable salt, hydrate or ester thereof. Also provided is a composition comprising the microparticles and a stabilizing agent.

Abstract: Compositions comprising the nitrate of arginine are disclosed. In some aspects, the nitrate of arginine is a salt of a nitric acid (NO3?) or a mixed salt of a nitric acid (NO3?). The compositions further comprise one or more additional components selected from the group consisting of a carrier, an excipient, a binder, a colorant, a flavoring agent, a preservative, a buffer, and a dilutant. In one aspects, the composition is in a dosage form selected from the group consisting of a capsule, a cachet, a pill, a tablet, a powder, a granule, a pellet, a bead, a particle, a troche, and a lozenge. In other aspects, the composition is for human ingestion. In some embodiments, the composition, for example the composition for human ingestion, is a human dietary supplement.

Abstract: The invention relates, in part, to nanoparticles, methods for preparing nanoparticles and methods of administering nanoparticles for immune stimulation. An immune-stimulating nanoparticle of the invention may include, at least in part, a polymer substrate comprising a biodegradable polymer and may include at least one antigen and/or at least one adjuvant.

Abstract: Dendritic cells containing tumor lysate loaded particles are prepared. The dendritic cells present tumor antigens to elicit the Major Histocompatibility Complex class I pathway and can be used as a vaccine to treat cancer, including ocular melanoma.

Abstract: The method of producing eggshell-derived nanoparticles may include steps of adding eggshell powder to methanol to form a solution; adding the solution dropwise to boiling water under ultrasonic conditions; incubating the resulting solution under continuous stirring at 200-800 rpm; and drying the resulting solution to obtain the eggshell-derived nanoparticles. The method produces nanoparticles of between 5 and 100 nm. Cytotoxicity testing shows that the nanoparticles exhibit anticancer activity against human breast cancer and lung cancer cell lines.

Abstract: A process for purifying an extracted material extracted from a biomass material, providing a raw extracted material comprising an amount of a solvent or an extractable compound, heating the raw extracted material to a temperature sufficient to provide and maintain a flowable form, and to raise the partial pressure of the solvent or the extractable compound, increasing the surface area of the raw extracted material, passing a purifying gas across the increased surface area of the raw extracted material, to remove solvent and the extractable compound into the purifying gas to produce a stripped extract material, exposing the stripped extract material to a vacuum pressure to remove residual purifying gas, solvent, and the extractable compound to produce a first-stage purified extract material, and repeating one or more times to prepare a purified extract material.

Abstract: The present invention provides novel pharmaceutical compositions comprising -(4-Chloro-2-(morpholin-4-yl)thiazol-5-yl)-7-(1-ethylpropyl)-2,5-dimethylpyrazolo(1,5-a)pyrimidine and methods of using the same for the treatment of Congenital adrenal hyperplasia (CAH).

Abstract: Compositions and methods for the prevention, inhibition, and/or treatment of progressive fibrosis present in various fibroproliferative disorders. Embodiments relate to the use of Sigma-1 receptor agonists for use in the treatment of prevention of progressive fibrosis characterized by the over proliferation of ECM producing cells, e.g. myofibroblasts and by the excessive deposition of ECM components in a medical or disease condition. Preferred Sigma-1 agonists are disclosed.

Abstract: The present invention relates to a lactoferrin-conjugated nanoparticle complex and a novel use thereof. In the nanoparticle complex according to the present invention, lactoferrin or polyethylene glycol-lactoferrin is bound to metal nanoparticles, and according to this construction, it can be confirmed that the metal nanoparticles are not only efficiently targeted to the brain tumor tissues, but also the stability of the metal nanoparticles can be maintained even in the in vivo conditions, and thus it is expected in the treatment of brain tumors to be treatable to targets by approaching more fundamentally.

Abstract: Polymeric compositions are described comprising a biocompatible polymer including a biodegradable linkage to a visualization agent and a non-physiological solution; wherein the biocompatible polymer is soluble in the non-physiological solution and insoluble in a physiological solution. Methods of forming the solutions and polymers are disclosed as well as methods of therapeutic use.

Abstract: Microbiota restoration therapy (MRT) compositions (e.g., oral MRT compositions) and methods for manufacturing MRT compositions are disclosed. An example method for manufacturing an MRT composition may include collecting a stool sample, purifying the stool sample to form a purified sample, stabilizing the purified sample to form a stabilized sample, converting the stabilized sample to a solid, adding one or more additives and/or excipients to the solid to form a treatment composition, and encapsulating the treatment composition.

Abstract: A light-emitting material, a method for producing the light-emitting material and a display apparatus are provided. An average particle size of the light-emitting material is 0.1 ?m to 30 ?m, and an average distance between outermost quantum dots of a particle of the light-emitting material and a surface of the particle of the light-emitting material is 0.5 nm to 25 nm, or a minimum distance between the outermost quantum dots of a particle of the light-emitting material and the surface of the particle of the light-emitting material is 0.1 nm to 20 nm.

Abstract: The present invention relates to the use of an Angiotensin II type 1 (AT1) receptor blocker for promoting sleep and/or the treatment of insomnia. It is based, at least in part, on the results of experiments performed using a validated rat model of stress-induced insomnia in which candesartan was found to ameliorate sleep disturbances induced by stress. Further, it was observed that this effect seems to be caused by blockade of AT1 receptors located in several brain regions that are key components of the neural circuitry activated during insomnia. In contrast to currently marketed treatments for insomnia, the AT1 receptor blocker was found to restore normal sleep without inhibiting REM sleep and/or inducing atypical wave components in the EEG.

Abstract: The present invention relates to a method for the cosmetic treatment of keratin fibres, in particular human keratin fibres such as the hair, characterized in that it consists in applying an effective amount of a cosmetic composition comprising an aqueous dispersion of hydrophobic silica aerogel particles comprising at least one alcohol of formula (I) below, the optical isomers thereof and the solvates thereof, in particular the hydrates thereof: in which formula (I): R1 represents an —OH, —CH2OH or —CH3 group; R2 represents a hydrogenatom or an —OH group; R3 represents a hydrogen atom, a —CH2OH group, an —(O—CH2—CH2)n-OH group with n denoting an integer ranging from 1 to 10, a —(CH2—CH2)n—OH group with n denoting an integer ranging from 1 to 5 or a —CH(OH)—CH3 group, 20 the formula comprising at least one hydroxyl group.

Abstract: A pharmaceutical composition comprises a metal nanoparticle having an average diameter of about 0.5 nm to about 5 nm. The composition may be used to treat cancer or an anosmia-related disease.

Abstract: The invention relates to HER3/HER2 bispecific antibodies binding to the beta-hairpin of HER3 and domain II of HER2, their preparation and use as medicament.

Abstract: The invention relates to plant-derived cellulose-containing particles useful as rheology modifiers and to a process for preparing cellulose-containing particles from plant material, which process involves treating said plant material with a peroxide reagent. The process can be controlled to produce cellulose-containing particle having a viscosity up to about 7500 or 8000 cps.

Abstract: An aerosol-generating system is provided, including an aerosol-generating device including a heater element; an aerosol-generating article, including a medicament source and a volatile delivery enhancing compound source; and at least one resilient member provided in the aerosol-generating device or the aerosol-generating article and being resiliently biased against the heater element, wherein at least one of the medicament source and the volatile delivery enhancing compound source contacts the at least one resilient member, and the aerosol-generating system is configured to heat the medicament source and the volatile delivery enhancing compound source of the aerosol-generating article so that the medicament source has a higher temperature than that of the volatile delivery enhancing compound source.

Abstract: The present invention discloses a novel compound with effects of thrombolysis, free radical scavenging and thrombus-targeting, as well as a preparation method and use thereof. The compound is a ternary conjugate formed by conjugating a thrombolytic peptide, a free radical scavenger and a thrombus-targeting/antithrombotic peptide together via a linking arm. The present invention also discloses a pharmaceutical composition containing the compounds, wherein the compounds form a nanospherical structure.